BRIEF

on ABIVAX (EPA:ABVX)

Abivax recruits first patient for its clinical trial on Crohn's disease

Stock price chart of ABIVAX (EPA:ABVX) showing fluctuations.

Biotechnology company Abivax announced the enrollment of the first patient in its Phase 2b ENHANCE-CD clinical trial. This trial aims to evaluate the efficacy and safety of the drug obefazimod in patients with Crohn's disease.

Designed as a double-blind, multicenter trial, it includes a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase. The primary objective is to analyze the safety and tolerability of obefazimod compared to placebo.

This advance could offer a convenient oral therapeutic option for people with moderately to severely active disease.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all ABIVAX news